Table 1

Independent masked adjudication of intercurrent events of additional anti-inflammatory treatment according to three clinical phenotypes of Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS)

Entire trial cohort, n=75n=37n=380.04
ICENone13 (35%)21 (55%)
Indicated13 (35%)14 (37%)
Non-indicated11 (30%)3 (8%)
Shock-like, n=20n=10n=100.77
ICENone2 (20%)3 (30%)
Indicated6 (60%)6 (60%)
Non-indicated2 (20%)1 (10%)
Kawasaki disease-like, n=31n=15n=160.10
ICENone9 (60%)8 (50%)
Indicated2 (13%)7 (44%)
Non-indicated4 (27%)1 (6%)
Undifferentiated, n=24n=12n=120.004
ICENone2 (16%)10 (84%)
Indicated5 (42%)1 (8%)
Non-indicated5 (42%)1 (8%)
  • Considering the non-indicated ICEs among patients classified as having Kawasaki disease-like and undifferentiated PIMS-TS at baseline, all were considered to be Kawasaki disease-like at the time of ICE; among patients with undifferentiated PIMS-TS at baseline and non-indicated ICEs, three episodes were reclassified as Kawasaki disease-like PIMS-TS at the time of the ICE, one was considered to be Shock-like PIMS-TS with improvement and one was considered undifferentiated PIMS-TS.

  • ICE, intercurrent event; IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone.